Testing a new medication to slow muscle weakness in early-stage ALS

This study is testing a new medication called Usnoflast to see if it can help slow down ALS, a disease that affects the muscles and gradually makes it harder to move, speak, and breathe. About 240 people with early-stage ALS will take either Usnoflast at different doses or a placebo (inactive pill) for 36 weeks, so researchers can compare how well the medication works. After that, participants can continue taking the treatment for another 16 weeks to help confirm it's safe over the long term.

ALS is a serious disease with limited treatment options, and current medications only slow it down modestly. Researchers are testing this medication to see if it might be more effective at protecting nerve cells and slowing muscle weakness in people newly diagnosed with the disease.